# CT‐Guided Cryoablation Achieves Significantly Higher Local Tumor Control in Sub‐Solid Lung Tumors Compared With Solid Tumors: A Retrospective Cohort Study

**Authors:** Tongyin Zhang, Qiaoyu Xu, Haoyu Li, Yuwan Hu, Haoran Du, Zhenguo Huang, Yanyan Xu, Meng Yang, Hongliang Sun

PMC · DOI: 10.1111/1759-7714.70253 · 2026-02-20

## TL;DR

CT-guided cryoablation is effective and safe for treating both solid and sub-solid lung tumors, with better local tumor control in sub-solid tumors.

## Contribution

Demonstrates superior local tumor control in sub-solid lung tumors compared to solid tumors using CT-guided cryoablation.

## Key findings

- CT-guided cryoablation achieved 100% technical success rate in treating lung tumors.
- Local tumor control was 100% for sub-solid tumors versus 74% for solid tumors.
- Procedure had a low rate of major complications (4%) and favorable 24-month overall survival rate of 100%.

## Abstract

Cryoablation has proved to be an effective method to cure lung cancer based upon existing research, thus has been widely used in clinical practice. This pilot study aimed to evaluate the efficacy and safety of CT‐guided cryoablation for the treatment of different lung tumors, including solid and sub‐solid lung tumors.

This retrospective study enrolled a total of 77 patients with lung tumors, comprising 46 solid tumors and 31 sub‐solid tumors. All patients underwent CT‐guided cryoablation. The various aspects of the treatment, including procedural details, technical success rate, complications, and local tumor control were systematically evaluated.

The technical success rate of CT‐guided cryoablation was 100%. The procedure was well‐tolerated, with a low rate of major complications (4%). The most common complication is pneumothorax, which presents in 34.8% of patients with solid tumors as well as 51.6% of patients with sub‐solid tumors. The incidence rates of all the complications were not statistically different. The median follow‐up period was 24 months, during which local tumor control rates were 74% for solid lung tumors and 100% for sub‐solid tumors. The overall survival rates at 24 months were 100%.

CT‐guided cryoablation appears to be an effective and safe treatment modality for different lung tumors, including solid and sub‐solid tumors. The high technical success rate, low rate of major complications, and favorable local tumor control suggest that cryoablation could serve as a valuable alternative treatment especially for the tumors manifesting as sub‐solid tumors.

CT‐guided cryoablation is an effective and safe treatment for both solid and sub‐solid lung tumors, achieving 100% technical success. It demonstrates favorable local control, particularly for sub‐solid nodules, with a low rate of major complications.

## Linked entities

- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Diseases:** Complications (MESH:D008107), SCLC (MESH:D055752), PSN (MESH:D016606), pain (MESH:D010146), Solid Tumors (MESH:D009369), adenocarcinoma (MESH:D000230), compromised lung (MESH:D008171), pulmonary artery pseudoaneurysm (MESH:D017541), Lung Tumors (MESH:D008175), pulmonary nodules (MESH:D055613), rectal cancer metastases (MESH:D012004), emphysema (MESH:D004646), lung adenocarcinoma (MESH:D000077192), Pleural effusion (MESH:D010996), Hemoptysis (MESH:D006469), adenocarcinomas in situ (MESH:D065311), NSCLC (MESH:D002289), lung squamous cell carcinoma (MESH:D002294), DM (MESH:D009362), PGGN (MESH:C000721427), HLOS (MESH:D003428), colorectal cancer (MESH:D015179), Pneumothorax (MESH:D011030), air embolization (MESH:D004618), coagulation disorders (MESH:D001778), lymph node metastasis (MESH:D008207), RLN (MESH:D000072717), interstitial lung disease (MESH:D017563), fistula (MESH:D005402), necrosis (MESH:D009336), solid (MESH:D018250), renal carcinoma (MESH:D002292)
- **Chemicals:** helium (MESH:D006371), MDT (-), argon (MESH:D001128)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C-40 C, C for 10-15, C to -160

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962398/full.md

---
Source: https://tomesphere.com/paper/PMC12962398